Biotech Values

[pcrutch]

"Abstract 6507: Single-agent ibrutinib showed a 73% ORR (65% PR 8% CR) in elderly (71 years 65-84) treatment naive patients with CLL at 10.7 months median follow-up."

This data is even more impressive when you consider 74% were older than 70.